Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| MESO | PRESS-RELEASE | bullish | 7/10 | Mesoblast reported FY2026 total revenue of $120.3M, up 7x from $17.2M in FY2025, driven by the first full year of RYONCI | Aug 26, 2026 |
| IMRX | PRESS-RELEASE | neutral | 4/10 | Immuneering issued a press release commenting on the recent FDA approval of a new second-line pancreatic cancer treatmen | Aug 26, 2026 |
| RVMD | PRESS-RELEASE | bullish | 8/10 | Revolution Medicines received FDA approval for RASONQUE (daraxonrasib) for metastatic pancreatic adenocarcinoma after at | Aug 26, 2026 |
| ROIV | PRESS-RELEASE | bullish | 6/10 | Priovant Therapeutics (a Roivant company) published skin-specific outcomes from the Phase 3 VALOR trial of brepocitinib | Aug 26, 2026 |
| BBIO | PRESS-RELEASE | bullish | 7/10 | BridgeBio announced first patient dosed in ASCEND-ATTR, a Phase 3b/4 study of acoramidis in ATTR-CM, designed to assess | Aug 26, 2026 |
| CELU | PRESS-RELEASE | bearish | 7/10 | Celularity Inc. disclosed it received a Nasdaq delinquency notice for failing to file its Q1 and Q2 2026 quarterly repor | Aug 25, 2026 |
| AVXL | PRESS-RELEASE | neutral | 5/10 | Anavex Life Sciences reported a GAAP net income of $7.8M for Q3 fiscal 2026, driven by a reversal of stock-based compens | Aug 25, 2026 |
| SGMT | PRESS-RELEASE | neutral | 4/10 | Sagimet announced its AURORA Phase 3 trial of denifanstat for moderate-to-severe acne is on track to begin enrollment in | Aug 25, 2026 |
| GRML | PRESS-RELEASE | bullish | 7/10 | Greenland Mines announced a landmark S-K 1300 Technical Report Summary for its Sarfartoq Nd-Pr Rare Earths Project, prep | Aug 24, 2026 |
| QNTM | PRESS-RELEASE | neutral | 2/10 | Quantum BioPharma granted 572,500 stock options to directors, officers, employees, and consultants at C$4.80 per share, | Aug 21, 2026 |
| IOVA | PRESS-RELEASE | neutral | 2/10 | Iovance Biotherapeutics granted inducement stock options covering 240,135 shares to 20 new non-executive employees at an | Aug 21, 2026 |
| GRML | PRESS-RELEASE | bullish | 6/10 | Greenland Mines Ltd received Greenland government approval to transfer a key mineral exploration license for the Sarfart | Aug 21, 2026 |
| LFVN | PRESS-RELEASE | neutral | 2/10 | LifeVantage declared a quarterly cash dividend of $0.050 per share, payable September 15, 2026 to holders of record Sept | Aug 21, 2026 |
| SNYR | PRESS-RELEASE | bearish | 8/10 | Synergy CHC Corp. (SNYR) disclosed a Nasdaq non-compliance notice for late filing of its Q2 2026 Form 10-Q. The company | Aug 21, 2026 |
| HOWL | PRESS-RELEASE | bearish | 7/10 | Werewolf Therapeutics (HOWL) announced a definitive all-stock merger with Ambros Therapeutics, valuing Ambros at $500M a | Aug 21, 2026 |
| MIST | PRESS-RELEASE | bullish | 7/10 | Milestone Pharmaceuticals announced first patient enrollment in the Phase 3 ReVeRA-301 pivotal trial evaluating etripami | Aug 21, 2026 |
| RNA | PRESS-RELEASE | neutral | 2/10 | Atrium Therapeutics granted inducement stock options and RSUs totaling 11,000 shares and 5,500 shares, respectively, to | Aug 20, 2026 |
| CELZ | PRESS-RELEASE | neutral | 5/10 | Creative Medical Technology announced that all patients have been enrolled and treated across its ADAPT clinical trial f | Aug 20, 2026 |
| SLGL | PRESS-RELEASE | neutral | 4/10 | Sol-Gel reported Q2 2026 EPS of -$1.13, beating consensus of -$2.31 by 51.1%, but revenue plunged to $0.6M from $17.3M a | Aug 20, 2026 |
| EVAX | PRESS-RELEASE | neutral | 4/10 | Evaxion reported Q2 2026 net loss of $3.7M, in line with expectations and improved from $4.8M a year ago, with cash of $ | Aug 20, 2026 |
| NBP | PRESS-RELEASE | bearish | 6/10 | NovaBridge Biosciences reported H1 2026 net loss of $37.9M ($0.14 per share), widening from $8.7M ($0.05) a year ago, as | Aug 20, 2026 |
| RADX | PRESS-RELEASE | neutral | 4/10 | Radiopharm Theranostics announced a positive DSMC recommendation to advance its radiotherapeutic RAD202 to the next dose | Aug 20, 2026 |
| ACIU | PRESS-RELEASE | neutral | 5/10 | AC Immune announced positive preliminary Phase 1 data for its wholly-owned NLRP3 inhibitor ACI-19764, showing safety, to | Aug 20, 2026 |
| EDSA | PRESS-RELEASE | bearish | 7/10 | Edesa Biotech priced a $25M underwritten public offering of common shares and warrants at $5.50 per unit, with an additi | Aug 19, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix Pharmaceuticals reported H1 2026 revenue of $477M, up 22% YoY, and a net profit of $38M vs a loss of $2M in H1 202 | Aug 19, 2026 |
| AAPG | PRESS-RELEASE | bearish | 6/10 | Ascentage Pharma reported H1 2026 revenue of $44.5M, up 29% YoY, driven by product sales growth of 32.6%. However, the n | Aug 19, 2026 |
| ALVO | PRESS-RELEASE | bearish | 6/10 | Alvotech reported Q2 2026 adjusted EPS of -$0.11, missing consensus of -$0.08 by 30.2%. H1 2026 total adjusted revenue f | Aug 19, 2026 |
| ELAB | PRESS-RELEASE | neutral | 3/10 | PMGC Holdings (ELAB) announced a 1-for-10 reverse stock split effective August 21, 2026, reducing outstanding shares fro | Aug 19, 2026 |
| CMMB | PRESS-RELEASE | bearish | 6/10 | Chemomab Therapeutics reported Q1 2026 EPS of -$0.24, a 51.8% miss vs consensus of $0.00, with no revenue. The planned m | Aug 19, 2026 |
| HUMA | PRESS-RELEASE | bullish | 6/10 | Humacyte announced publication of one-year Phase 3 V007 trial results in The Lancet Digital Health, showing ATEV superio | Aug 19, 2026 |